Rigel Pharmaceuticals, Inc. (RIGL)

1,2000 +0,0500 (+4,35%) Börsenschluss: 04:00PM EDT

Rigel Pharmaceuticals, Inc.

611 Gateway Blvd
Suite 900
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 147

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Raul R. Rodriguez	President, CEO & Director	1,17M	N/A	1961
Mr. Dean L. Schorno CPA	Executive VP & CFO	736,72k	N/A	1963
Mr. Raymond J. Furey J.D.	Executive VP, General Counsel & Corporate Secretary	683k	N/A	1968
Mr. David A. Santos	Executive VP & Chief Commercial Officer	737,18k	N/A	1963
Ms. Julie Patel	Senior VP of Human Resources	N/A	N/A	N/A
Dr. Esteban S. Masuda	Executive Vice President of Research	537,21k	N/A	1962
Mr. Joseph Lasaga	Executive VP & Chief Business Officer	N/A	N/A	1975
Dr. Lisa Rojkjaer M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1966
Mr. Tarek Sallam	Vice President of Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Corporate Governance

Rigel Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 3, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.